News Headlines

  1. TrialScope A CARE Finalist For Best Patient-Focused Technology
    2/25/2019

    TrialScope has been named a finalist for Best Patient-Focused Technological Development in the CARE Awards, which recognize outstanding work across the global clinical research enterprise.

  2. DiaMedica Therapeutics Doses First Patient In Phase 1b Clinical Study Of DM199 In Patients With Chronic Kidney Disease
    2/15/2019

    DiaMedica Therapeutics Inc., a clinical-stage biotechnology company, recently announced that it has initiated dosing patients with chronic kidney disease (“CKD”) in a Phase Ib clinical study evaluating DM199.

  3. United BioSource LLC (UBC) Opens A New 43,000 Square Foot Facility In Lake Mary, Florida
    2/14/2019

    UBC, a global leading provider of late-stage and patient support services, held a ribbon-cutting ceremony for the grand opening of a 43,000 square foot facility located at 680 Century Point, Lake Mary, FL due to expansion of the business.

  4. TYME Reports Encouraging SM-88 Clinical Results Without Typical Hormone-Related Side Effects In Phase II Study Of Patients With Biomarker Recurrent Prostate Cancer
    2/14/2019

    Tyme Technologies, Inc. (NASDAQ:TYME), an emerging biotechnology company developing metabolic-based cancer therapies, announced encouraging preliminary results from an ongoing Phase II trial of SM-88 in patients with non-metastatic, biochemical-recurrent prostate cancer.

  5. ADC Therapeutics Announces First Patient Dosed In Phase I Clinical Trial Of ADCT-402 (Loncastuximab Tesirine) And IMFINZI® (Durvalumab) In Multiple Types Of Advanced Non-Hodgkin Lymphoma
    2/13/2019

    ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in a Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-402 (loncastuximab tesirine) plus AstraZeneca’s IMFINZI® (durvalumab) in patients with advanced diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) or follicular lymphoma (FL).

  6. Conatus Announces Completion Of Enrollment In ENCORE-LF Phase 2b Clinical Trial Of Emricasan In Patients With Decompensated NASH Cirrhosis
    2/13/2019

    Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the completion of enrollment in ENCORE-LF, a Phase 2b clinical trial evaluating emricasan, the company’s first-in-class, orally-active pan-caspase inhibitor.

  7. Sharp Clinical Invests $650,00 Into Interactive Response Technology (IRT) Solutions
    2/13/2019

    Sharp has announced a $650,000 investment into enhancing its Interactive Response Technology (IRT) solution. Sharp’s IRT solution is used to manage patient interactions and drug supplies during clinical trials and perform a range of functions for sponsors, drug depots and investigative sites.

  8. Single-Use Technology For Biologics Manufacturing In St. Louis, Missouri
    2/12/2019

    Watch this video and learn about Thermo Fisher Scientific’s expansion of its biologics site in St. Louis, Missouri. The facility will be the single largest single-use technology CDMO in North America. 

  9. Thermo Fisher Receives Commercial Licenses for Two Biologic Therapies
    2/12/2019

    In 2018, the Pharma Services biologics business within Thermo Fisher Scientific, supported the commercialization of two new therapeutics for its clients. The St. Louis, Missouri and the Groningen, Netherlands sites both completed FDA Pre-Approval Inspections (PAIs) and received Establishment Inspection Reports (EIRs) for the commercial manufacture of biologic therapies.

  10. Aduro Announces First Patient Dosed In Phase 1 Study Of ADU-S100 (MIW815) In Combination With YERVOY (ipilimumab) For The Treatment Of Relapsed And Refractory Melanoma
    2/12/2019

    Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that the first patient has been dosed in a Phase 1 trial of ADU-S100 (MIW815), a novel stimulator of interferon genes (STING) pathway activator, in combination with YERVOY® (ipilimumab), an approved anti-CTLA-4 antibody for the treatment of relapsed and refractory melanoma.